Template:Ceftizoxime: Difference between revisions

Jump to navigation Jump to search
mNo edit summary
mNo edit summary
 
(One intermediate revision by the same user not shown)
Line 17: Line 17:
|-
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Ceftizoxime adverse reactions|Adverse Reactions]]
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Ceftizoxime adverse reactions|Adverse Reactions]]
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Ceftizoxime overdosage|Overdosage]]
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Ceftizoxime clinical studies|Clinical Studies]]
|-
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Ceftizoxime dosage and administration|Dosage and Administration]]
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Ceftizoxime dosage and administration|Dosage and Administration]]
|-
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Ceftizoxime how supplied|How Supplied]]
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Ceftizoxime how supplied|How Supplied]]
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Ceftizoxime labels and packages|Labels and Packages]]
|-
|-
|}
|}

Latest revision as of 04:30, 31 December 2013